文献速递复苏、休克与脓毒症心脑血管急症重症综合管理与镇静镇痛

澳大利亚难治性院外心脏骤停患者从现场快速转运:一项前瞻性、多中心、平行、开放标签、随机临床试验

Expedited transfer from the scene for refractory out-of-hospital cardiac arrest in Australia: a prospective, multicentre, parallel, open label, randomised clinical trial.
PubMed 文献 · Lancet Respir Med · 2025-08-22
一句话结论难治性院外心脏骤停中,快速转运联合持续复苏较延长现场复苏未显著改善出院时神经功能良好生存(15% vs 16%,风险差-1.1%)。

该研究在澳大利亚大悉尼地区开展前瞻性、多中心、平行、开放标签、优效性随机试验,纳入18-70岁目击性院外心脏骤停、旁观者CPR、初始可除颤心律或无脉电活动且经15分钟高级生命支持或三轮专业复苏未恢复自主循环的患者,现场1:1随机至快速转运组(预设快速院前处理包+机械按压下转运至15家心脏导管中心评估冠脉造影和/或ECPR)或标准组(延长现场高级生命支持后再考虑转运)。197例纳入分析(快速组102例,标准组95例),出院时神经功能良好生存(CPC 1-2)快速组15%(15/102)vs 标准组16%(15/95),风险差-1.1%(95%CI -12.2%至10.0%),调整相对风险0.95(95%CI 0.50至1.8),p=0.87。严重不良事件38例(19%),两组分布均匀,无意外不良事件。结论:快速转运未显著改善神经功能良好生存,但研究可能把握度不足。

要点

  • 难治性OHCA(目击、旁观者CPR、初始可除颤心律或无脉电活动,经15分钟ALS或三轮专业复苏未ROSC)快速转运组出院神经功能良好生存15%(15/102)vs 标准组16%(15/95),风险差-1.1%(95%CI -12.2%至10.0%),未达统计学显著。
  • 调整相对风险0.95(95%CI 0.50至1.8),p=0.87,快速转运策略未显示优效。
  • 严重不良事件38例(19%),其中35例(92%)为缺氧性脑损伤(快速组17例[49%],标准组18例[51%]),两组分布均匀。
  • 作者认为研究可能把握度不足,无法检测小于预期的治疗效应。

适用人群与场景

  • 纳入标准:年龄18-70岁,目击性院外心脏骤停,推测为内科原因,旁观者实施心肺复苏,初始为可除颤心律或无脉电活动,且经15分钟高级生命支持或三轮专业复苏未恢复自主循环。
  • 研究场景:澳大利亚大悉尼地区,由新南威尔士救护车急救员在现场随机分组,转运至15家心脏导管中心。

诊断标准与关键阈值

  • 神经功能良好结局定义:出院时脑功能分类(CPC)评分1-2分。
  • 难治性定义:经15分钟高级生命支持或三轮专业复苏未恢复自主循环。

处置流程与药物剂量

  • 快速转运组:预设的快速院前处理包,随后在机械按压下进行心脏骤停期间转运至心脏导管中心,立即评估冠状动脉造影、体外心肺复苏(ECPR)或两者。
  • 标准组:延长现场高级生命支持后再考虑转运,并接受相同的治疗。

研究设计与关键结果

  • 研究类型:前瞻性、多中心、平行、开放标签、优效性随机临床试验,纳入197例患者(快速转运组102例,标准转运组95例)。
  • 主要终点:出院时神经功能良好生存(CPC 1-2),快速转运组15%(15/102)vs 标准组16%(15/95),风险差-1.1%(95%CI -12.2%至10.0%),调整相对风险0.95(95%CI 0.50至1.8),p=0.87。
  • 不良事件:38例(19%)发生严重不良事件,其中35例(92%)为缺氧性脑损伤(快速组17例[49%],标准组18例[51%]),1例(3%)脑卒中、1例(3%)肺出血、1例(3%)消化道出血(均在标准组);不良事件两组分布均匀,无意外不良事件。
  • 随访:至死亡或6个月(最后1例随访日期2024年8月29日)。

证据类型、等级与局限

  • 证据类型:前瞻性、多中心、平行、开放标签、优效性随机临床试验。
  • 局限:研究可能把握度不足,无法检测小于预期的治疗效应(原文作者自述)。

对床旁实践的改变

  • 对于符合纳入标准的难治性院外心脏骤停患者,快速转运策略与延长现场复苏策略相比,出院时神经功能良好生存无显著差异(15% vs 16%,p=0.87)。
  • 作者认为研究可能把握度不足,无法检测小于预期的治疗效应。

指南或共识出处

  • 澳大利亚临床试验注册号:ACTRN12621000668808。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The benefit of expedited intra-arrest transport with ongoing resuscitation versus more extended on-scene resuscitation for refractory out of hospital cardiac arrest (OHCA) is uncertain. We aimed to determine whether expedited intra-arrest transfer to hospital in adults with refractory OHCA improves favourable neurological outcomes.

METHODS: We conducted a prospective, parallel, multi-centre, open-label randomised, superiority trial across greater Sydney, NSW, Australia. Patients aged 18-70 years with a witnessed OHCA of presumed medical cause, bystander cardiopulmonary resuscitation (CPR), and an initial shockable rhythm or pulseless electrical activity without return of spontaneous circulation after 15 mins of advanced life support or three rounds of professional resuscitation were randomly assigned (1:1) at the scene by New South Wales Ambulance paramedics using a secure online randomisation system. Masking of allocation from ambulance staff and hospital staff receiving the patients was not possible. The intervention consisted of a predefined expedited bundle of pre-hospital care followed by intra-arrest transport with mechanical compression to a cardiac catheterisation centre (15 receiving hospitals) for immediate assessment for coronary angiography, extracorporeal cardiopulmonary resuscitation (ECPR), or both. The control arm consisted of a standard transport strategy of more extended on-scene advanced life support before considering transport and the same therapies. The primary outcome was survival with a good neurological outcome (defined as Cerebral Performance Category [CPC] score of 1-2) at hospital discharge, stratified by initial rhythm. Patients were followed-up until death or for 6 months (last patient followed-up Aug 29, 2024). All analyses were done on an intention-to-treat basis. The trial was prospectively registered with the Australian Clinical Trials Registry, ACTRN12621000668808 and is now complete. Data on safety and adverse events were collected throughout the study period and reported to a data safety monitoring board on a 6 monthly basis.

FINDINGS: Between July 15, 2021 and March 3, 2024, we enrolled 206 patients. Eight patients were later deemed to be ineligible and one patient was excluded due to a randomisation application failure. 197 patients were therefore enrolled; 102 to the expedited strategy (intervention) and 95 to the standard strategy (control). The median age was 57·0 years (range 47-64); 161 (82%) were men and 78 (40%) were White. At hospital discharge, 15 (15%) of 102 patients in the expedited transportation group were alive with a favourable neurological outcome, compared with 15 (16%) of 95 patients in the standard care group (risk difference -1·1% [95% CI -12·2% to 10·0%]; adjusted relative risk 0·95 [95% CI 0·50 to 1·8], p=0·87). 38 patients had a serious adverse event (19%)-35 (92%) were diagnosed with a hypoxic brain injury (17 [49%] in the expedited arm, 18 [51%] in the standard arm), one (3%) had a cerebral stroke, one (3%) had a pulmonary haemorrhage, and one (3%) had a gastrointestinal haemorrhage (all in the standard arm). Adverse events were evenly distributed between treatment arms. No unanticipated (ie, expected sequelae seen in a cardiac arrest trial or in intensive care) adverse events were identified.

INTERPRETATION: Among patients with refractory out-of-hospital cardiac arrest, expedited intra-arrest transport did not significantly improve survival with neurologically favourable outcome. However, the study might have been underpowered to detect a smaller than expected treatment effect.

FUNDING: New South Wales Health Translational Research Grant Scheme (H20/93572).

来源:Lancet Respir Med,查看原文。版权归原作者所有。

参考来源

  1. Burns B, Marschner IC, Buscher H, et al. Expedited transfer from the scene for refractory out-of-hospital cardiac arrest in Australia: a prospective, multicentre, parallel, open label, randomised clinical trial. Lancet Respir Med. 2025. PMID: 40854321. doi:10.1016/S2213-2600(25)00130-4

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。